Skip to main content
SpringerLink
Log in

Clinical Virology: Diagnosis and Virologic Monitoring

  • Chapter
Book cover Hepatitis B Virus in Human Diseases

Part of the book series: Molecular and Translational Medicine ((MOLEMED))

  • 2047 Accesses

Abstract

The clinical course of an HBV infection is highly variable. The course may either be asymptomatic or may manifest clinically as an inflammatory liver disease with accompanying liver cell damage. Furthermore, the course of HBV infection is dynamic and transition between various phases of the disease is possible at any time. The assessment of several serological parameters allows the correct diagnosis of HBV infection as well as virological monitoring and differentiation of distinct phases of HBV infection. In addition, vaccine-induced immunity can be confirmed. The confirmation of an HBV infection and the correct classification is an indispensible prerequisite for appropriate management. The most common virological laboratory tests for the assessment of HBV infection are (quantitative) HBsAg, anti-HBc, HBeAg, anti-HBe and HBV DNA.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lok ASF, McMahon BJ. AASLD practice guidelines—chronic hepatitis B: update 2009. Hepatology. 2009;50(3):1–38.

    Article  Google Scholar 

  2. Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, et al. Prophylaxis, diagnosis and therapy of hepatitis B virus infection—the German guideline. Z Gastroenterol. 2011;49(7):871–930.

    Article  CAS  PubMed  Google Scholar 

  3. World Health Organisation. WHO | Hepatitis B [Internet]. World Health Organization; 2002 [cited 2015 Jan 12]. Available from: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index3.html

  4. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–85.

    Article  Google Scholar 

  5. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100(1):182–8.

    CAS  PubMed  Google Scholar 

  6. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis. 2013;33(2):167–77.

    Article  CAS  PubMed  Google Scholar 

  7. Shattock AG, Morris MC. Evaluation of commercial enzyme immunoassays for detection of hepatitis delta antigen and anti-hepatitis delta virus (HDV) and immunoglobulin M anti-HDV antibodies. J Clin Microbiol. 1991;29:1873–6.

    PubMed Central  CAS  PubMed  Google Scholar 

  8. Tang JR, Cova L, Lamelin JP, Baginski I, Vitvitski L, Gaudin JL, et al. Clinical relevance of the detection of hepatitis delta virus RNA in serum by RNA hybridization and polymerase chain reaction. J Hepatol. 1994;21:953–60.

    Article  CAS  PubMed  Google Scholar 

  9. Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Dény P, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol. 2005;43:2363–9.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Weber B. Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol. 2005;32:102–12.

    Article  CAS  PubMed  Google Scholar 

  11. Servant-Delmas A, Mercier-Darty M, Ly TD, Wind F, Alloui C, Sureau C, et al. Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples. J Clin Virol. 2012;53(4):338–45.

    Article  CAS  PubMed  Google Scholar 

  12. Zacher BJ, Moriconi F, Bowden S, Hammond R, Louisirirotchanakul S, Phisalprapa P, et al. Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol. 2011;18(11):1943–50.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Jaroszewicz J, Calle Serrano B, Wursthorn K, Deterding K, Schlue J, Raupach R, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol. 2010;52(4):514–22.

    Article  CAS  PubMed  Google Scholar 

  14. Nguyen T, Thompson AJ, Bowden S, Croagh C, Bell S, Desmond PV, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52(4):508–13.

    Article  CAS  PubMed  Google Scholar 

  15. Höner Zu Siederdissen C, Cornberg M. The role of HBsAg levels in the current management of chronic HBV infection. Ann Gastroenterol. 2014;27:105–12.

    PubMed Central  PubMed  Google Scholar 

  16. Chan HL-Y, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, et al. Hepatitis B surface antigen quantification: why and how to use it in 2011—a core group report. J Hepatol. 2011;55(5):1121–31.

    Article  PubMed  Google Scholar 

  17. Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol. 2006;78 Suppl 1:S66–70.

    Article  CAS  PubMed  Google Scholar 

  18. Carman WF. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat. 1997;4 Suppl 1:11–20.

    Article  PubMed  Google Scholar 

  19. Wursthorn K, Jaroszewicz J, Zacher BJ, Darnedde M, Raupach R, Mederacke I, et al. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. J Clin Virol. 2011;50(4):292–6.

    Article  CAS  PubMed  Google Scholar 

  20. Sonneveld MJ, Rijckborst V, Boucher CAB, Zwang L, Beersma MFC, Hansen BE, et al. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B. J Clin Virol. 2011;51(3):175–8.

    Article  CAS  PubMed  Google Scholar 

  21. Yang H-I, Lu S-N, Liaw Y-F, You S-L, Sun C-A, Wang L-Y, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.

    Article  CAS  PubMed  Google Scholar 

  22. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989;2:588–91.

    Article  CAS  PubMed  Google Scholar 

  23. Ingman M, Lindqvist B, Kidd-Ljunggren K. Novel mutation in hepatitis B virus preventing HBeAg production and resembling primate strains. J Gen Virol. 2006;87:307–10.

    Article  CAS  PubMed  Google Scholar 

  24. Rodella A, Galli C, Terlenghi L, Perandin F, Bonfanti C, Manca N. Quantitative analysis of HBsAg, IgM anti-HBc and anti-HBc avidity in acute and chronic hepatitis B. J Clin Virol. 2006;37:206–12.

    Article  CAS  PubMed  Google Scholar 

  25. Maruyama T, Schodel F, Iino S, Koike K, Yasuda K, Peterson D, et al. Distinguishing between acute and symptomatic chronic hepatitis B virus infection. Gastroenterology. 1994;106:1006–15.

    CAS  PubMed  Google Scholar 

  26. Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.

    Article  CAS  PubMed  Google Scholar 

  27. Chen C-J, Yang H-I, Iloeje UH. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49(5 Suppl):S72–84.

    Article  CAS  PubMed  Google Scholar 

  28. Quint WG, de Bruijn I, Kruining H, Heijtink RA. HBV-DNA detection by gene amplification in acute hepatitis B. Hepatology. 1990;12:653–6.

    Article  CAS  PubMed  Google Scholar 

  29. Chan HL-Y, Hui AY, Wong ML, Tse AM-L, Hung LC-T, Wong VW-S, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut. 2004;53(10):1494–8.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Janssen HLA, Van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005;365(9454):123–9.

    Article  CAS  PubMed  Google Scholar 

  31. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696–9.

    Article  CAS  PubMed  Google Scholar 

  32. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 1994;19(6):1513–20.

    Article  CAS  PubMed  Google Scholar 

  33. Zarski J-P, Sturm N, Guechot J, Paris A, Zafrani E-S, Asselah T, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56(1):55–62.

    Article  PubMed  Google Scholar 

  34. Friedrich-Rust M, Ong M-F, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134(4):960–74.

    Article  PubMed  Google Scholar 

  35. Wong GL-H, Chan HL-Y, Wong CK-Y, Leung C, Chan CY, Ho PP-L, et al. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. J Hepatol. 2014;60(2):339–45.

    Article  PubMed  Google Scholar 

  36. Robic MA, Procopet B, Métivier S, Péron JM, Selves J, Vinel JP, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol. 2011;55(5):1017–24.

    Article  PubMed  Google Scholar 

  37. Wong GLH, Wong VWS, Choi PCL, Chan AWH, Chan HLY. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther. 2010;31(10):1095–103.

    Article  PubMed  Google Scholar 

  38. Kim SU, Seo YS, Cheong JY, Kim MY, Kim JK, Um SH, et al. Factors that affect the diagnostic accuracy of liver fibrosis measurement by Fibroscan in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2010;32(3):498–505.

    Article  CAS  PubMed  Google Scholar 

  39. Locarnini S, Hatzakis A, Heathcote J, Keeffe EB, Liang TJ, Mutimer D, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther. 2004;9:679–93.

    CAS  PubMed  Google Scholar 

  40. Solmone M, Giombini E, Vincenti D, Rozera G, Testa A, Moscetti A, et al. Slow response to entecavir treatment in treatment-naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants. Antivir Ther. 2014;19(2):201–9.

    Article  CAS  PubMed  Google Scholar 

  41. Cornberg M, Höner Zu Siederdissen C. HBsAg seroclearance with NUCs: rare but important. Gut. 2014;63(8):1208–9.

    Article  CAS  PubMed  Google Scholar 

  42. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52(5):1611–20.

    Article  CAS  PubMed  Google Scholar 

  43. Jaroszewicz J, Ho H, Markova A, Deterding K, Wursthorn K, Schulz S, et al. Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther. 2011;16(6):915–24.

    Article  CAS  PubMed  Google Scholar 

  44. Van Bömmel F, Bartens A, Mysickova A, Hofmann J, Krüger DH, Berg T, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61(1):66–76.

    Article  PubMed  Google Scholar 

  45. Maasoumy B, Wiegand S, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect. 2015;21:606.e1–606.e10.

    Article  CAS  Google Scholar 

  46. Glebe D, Bremer CM. The molecular virology of hepatitis B virus. Semin Liver Dis. 2013;33(2):103–12.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl-Neuberg-Strasse 1, Hannover, 30625, Germany

    Christoph Höner zu Siederdissen, Markus Cornberg & Michael P. Manns M.D.

Authors
  1. Christoph Höner zu Siederdissen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Cornberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael P. Manns M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael P. Manns M.D. .

Editor information

Editors and Affiliations

  1. Chang Gung University, Chang Gung Memorial Hospital, Taipei, Taiwan

    Yun-Fan Liaw

  2. INSERM Unit 1052, Hospices Civils de Lyon, Lyon University, Lyon, France

    Fabien Zoulim

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

zu Siederdissen, C.H., Cornberg, M., Manns, M.P. (2016). Clinical Virology: Diagnosis and Virologic Monitoring. In: Liaw, YF., Zoulim, F. (eds) Hepatitis B Virus in Human Diseases. Molecular and Translational Medicine. Humana Press, Cham. https://doi.org/10.1007/978-3-319-22330-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22330-8_10

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-22329-2

  • Online ISBN: 978-3-319-22330-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation